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Defining Conditioning
Regimens for BMT—
Recognition of ‘‘Regimens of
Intermediate Intensity’’
In their recent paper, Giralt et al. (2009) [1]
addressed the issue of defining the criteria for classi-
fying a reduced-intensity conditioning (RIC) regi-
men. One of the reasons for addressing this
question was to enable the transplant community to
‘‘perform adequate retrospective and prospective
analyses of different regimens,’’ and for the compari-
son of the outcome following RIC compared to non-
RIC regimens. Criteria for the definition of an RIC
regimen included in this paper were ‘‘any regimen
that does not require stem cell support for hemopoi-
etic recovery and that results in low nonhematologictoxicity and mixed donor-recipient chimerism in
a substantial population of patients in the early
posttransplantation period.’’
As part of this work the authors categorized
a number of regimens as RIC, but excluded the
BEAM regimen. This classification is in agreement
with the definitions of the European Blood and Mar-
row Transplant (EBMT) Lymphoma Working Party
(LWP) who have also classified BEAM as a non-RIC
regimen.
We became interested in using BEAM condition-
ing for allogeneic bone marrow transplantation
(BMT) because it was a regimen with a well-recog-
nized efficacy as a conditioning regimen in autolo-
gous transplantation for lymphoma with a low
toxicity profile (\5% nonrelapse mortality [NRM]).
We have previously published our initial experience
with BEAM-alemtuzumab regimen as a conditioning
regimen prior to allogeneic stem cell transplantation
(ASCT) for lymphoproliferative diseases [2]. Similar
to other RIC regimens, the NRM was \10% at 1
year, and effective long-term disease control was
achieved. This was recognized in a recent paper
from the EBMT LWP, who, in a retrospective anal-
ysis of RIC versus myeloablative transplants for
Hodgkin lymphoma (HL), included BEAM in the
RIC group because of the reported low NRM and
good clinical outcome [3]. BEAM-alemtuzumab con-
ditioning is now being used in 2 National Cancer Re-
search Network (NCRN) Lymphoma trials in the
UK (for mantle cell lymphoma and refractory Hodg-
kin disease).
Although we have no problem with the nonclassi-
fication of BEAM-alemtuzumab as an RIC regimen by
Giralt et al. [1], and we agree that although it does not
qualify under the ‘‘Champlin criteria,’’ the problem is
that by default it becomes classified as a myeloblative
regimen and grouped with regimens that have a high
NRM, particularly in lymphoma.
This same point was eloquently made in a recent
paper by Marks et al. (2008) [4], who have used a reg-
imen comprising fludarabine (Flu), melphalan (Mel)
(140 mg/m2), and BCNU (400 mg/m2) plus antithy-
mocyte globulin (ATG) as a conditioning regimen
for a variety of hematologic malignancies. These
doses of BCNU and Mel are comparable to that
used in BEAM. In their article, Marks et al. [4] also re-
ported a low NRM of 3.7% at 1 year in patients with
early disease. Furthermore, this regimen had signifi-
cant antileukemic efficacy in patients with advanced
leukemia at transplant with event-free survival (EFS)
of 40% at 5 years. These authors concluded that dis-
ease control by (Flu/Mel) was similar to myeloablative
conditioning (MAC), but with regimen-related toxic-
ities and NRM comparable to that seen with RIC
regimens.
Biol Blood Marrow Transplant 15:886-891, 2009 891Letters to the EditorWe suggest that regimens such as BEAM-alemtu-
zumab and Fly-Mel/ATG, which combine low toxicity
and NRM with significant antitumor efficacy should
be classified as neither RIC nor myeloablative regi-
mens, but ‘‘regimens of intermediate intensity’’ or
‘‘toxicity-reduced conditioning’’ regimens. This is par-
ticularly important in avoiding the categorization of
such regimens as ‘‘myeloablative’’ in registry compari-
sons of outcome of RIC versus myeloblative-condi-
tioned transplants.
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doi:10.1016/j.bbmt.2009.02.012Response to LetterWe appreciate the comments of Professor Russell
and his colleagues regarding the report of our work-
shop. Our intent with this manuscript was not to
‘‘include’’ or ‘‘exclude’’ any regimen but to get a sense
of how members of the ‘‘transplant community’’ view
the current criteria as well as operational definitions
of what constitutes a ‘‘reduced intensity regimen’’.
The criteria were for the most part accepted by the
workshop participants. The operational definitions,
however, were not universally accepted. We did not
exclude the combination of carmustine, etoposide,
cytarabine and melphalan (BEAM) as a RIC regimen,
although 2/3 of the attendants did not feel that this
regimen should be included in the operational defini-
tion of RIC. In practice, some retrospective reviews
have included BEAM among the regimens analyzed.
Professor Russell correctly recognizes the arbitrary na-
ture of some of these definitions. However, our manu-
script was not intended to include or exclude any
regimen in particular, but to get a sense of what was
the ‘‘feeling’’ of the transplant community. The
CIBMTR and the EBMT are working on a consensus
statement to clarify some of these issues. In the end,
more important than classifying a regimen as ablative
or not, is whether any specific regimen will be associ-
ated with better outcomes. This will only be deter-
mined by prospective randomized trials.
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